ED50 of remimazolam combined with nalbuphine in painless hysteroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057555

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-05-05

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless hysteroscopy

Interventions

N1:Nalbuphine 0.1mg/kg

N2:Nalbuphine 0.15mg/kg

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective hysteroscopy, ASA grade I-II; 2. Aged 18-60 years; 3. BMI 18-24 kg/m2; 4. Normal communication; 5. Voluntary subjects and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe respiratory and circulatory diseases, such as severe coronary heart disease and COPD; 2. Diseases of the endocrine system, such as pituitary tumor, severe diabetes, hypercortisolism, pheochromocytoma; 3. Mental and psychological diseases, such as schizophrenia, depression, history of chronic analgesic drug use, history of alcohol abuse, opioid dependence; 4. History of allergy to anesthetic drugs.

Design outcomes

Primary

Measure	Time frame
Median effective dose;	—

Secondary

Measure	Time frame
dosage of remimalolam;dosage of Nalbuphine;Recovery time;Duration time given initial dose of remimalolam;Respiratory depression;Adverse reactions;Duration of procedure;Ramsay sedative score;hemodynamic parameters;Orientation recovery time;Behavioral Pain Scale-non intubated;Visual analogue scale;	—

Contacts

Public ContactXuesheng Liu

The First Affiliated Hospital of Anhui Medical University

liuxuesheng@ahmu.edu.cn+86 18655193385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026